CoChat
Sign Up
Cited by 316Cancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

Open access
Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B., Piperno-Neumann, S., Bernard, V., Baulande, S., Bieche, I., Pierga, J.Y., Proudhon, C., Bidard, F.-C.·2017·Annals of Oncology
DOI 10.1093/annonc/mdx212
Open this paper in CoChat — free account

Abstract

Background Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 antibodies. Radiological evaluation of ICB efficacy during therapy is challenging due to tumor immune infiltration. Changes of circulating tumor DNA (ctDNA) levels during therapy could be a promising tool for very accurate monitoring of treatment efficacy, but data are lacking with ICB.Patients and methods This prospective pilot study was conducted in patients with nonsmall cell lung cancer, uveal melanoma, or microsatellite-instable colorectal cancer treated by nivolumab or pembrolizumab monotherapy at Institut Curie. ctDNA levels were assessed at baseline and after 8 weeks (w8) by bidirectional pyrophosphorolysis-activated polymerization, droplet digital PCR or next-generation sequencing depending on the mutation type. Radiological evaluation of efficacy of treatment was carried out by using immune-related response criteria.Results ctDNA was detected at baseline in 10 out of 15 patients. At w8, a significant correlation (r = 0.86; P = 0.002) was observed between synchronous changes in ctDNA levels and tumor size. Patients in whom ctDNA levels became undetectable at w8 presented a marked and lasting response to therapy. ctDNA detection at w8 was also a significant prognostic factor in terms of progression-free survival (hazard ratio = 10.2; 95% confidence interval 2.5-41, P < 0.001) and overall survival (hazard ratio = 15; 95% confidence interval 2.5-94.9, P = 0.004).Conclusion This proof-of-principle study is the first to demonstrate that quantitative ctDNA monitoring is a valuable tool to assess tumor response in patients treated with anti-PD-1 drugs.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx212

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

Sorted by citations

Items 301–316 of 316

Related

See all

Metadata

Authors
Cabel, L., Riva, F., Servois, V., Livartowski, A., Daniel, C., Rampanou, A., Lantz, O., Romano, E., Milder, M., Buecher, B., Piperno-Neumann, S., Bernard, V., Baulande, S., Bieche, I., Pierga, J. Y., Proudhon, C., & Bidard, F.-C.
Affiliations
  • Inserm (FR)
  • Université Paris Descartes (FR)
  • Université Paris-Saclay (FR)
Corresponding author
Bidard, F.-C.
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-08
Volume
28
Issue
8
Pages
1996-2001
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdx212
OpenAlex
W2607977201
Cited by
315
References
23
Citations by year
2026: 11 · 2025: 20 · 2024: 19 · 2023: 59 · 2022: 49 · 2021: 30 · 2020: 43 · 2019: 37 · 2018: 34 · 2017: 12
FWCI
15.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
Agence Nationale de la Recherche (ANR-10-EQPX-0003)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
circulating tumor DNA, liquid biopsy, anti-PD-1 therapy, immune checkpoint inhibitors, nivolumab, pembrolizumab, treatment response monitoring, non-small cell lung cancer, uveal melanoma, progression-free survival, overall survival, prognostic factors
MeSH terms
Aged, Aged, 80 and over, DNA, Neoplasm, Female, Humans, Immunotherapy, Male, Middle Aged, Monitoring, Physiologic, Neoplasms, Pilot Projects, Prognosis, Prospective Studies, Survival Analysis, Polymerase Chain Reaction, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review